title: Stage I-II low-grade lymphomas: a prospective trial of combination chemotherapy and radiotherapy.
abstract: Between 1984-1989, 44 patients with stage I-II low grade lymphoma were treated prospectively with sequential chemotherapy and involved-field radiotherapy. The chemotherapy was cyclophosphamide, vincristine, prednisone, and bleomycin (COP-Bleo); doxorubicin was included (CHOP-Bleo) for patients with adverse prognostic features (high LDH; extranodal sites; bulky nodes). Of the 44 patients, 37 had measurable disease and all have responded. With a median follow-up of 32 months, the 5-year survival and failure-free survival were 89% and 74%, respectively. Compared to past experience with involved-field radiotherapy alone, the failure-free survival is significantly better with COP-Bleo plus radiotherapy. The potentially cured fraction has risen from 40% to 74%.
authors.affiliation: Department of Radiotherapy, University of Texas MD Anderson Cancer Center, Houston 77030.
authors.forename: P
authors.initials: P
authors.lastname: McLaughlin
authors.forename: L
authors.initials: L
authors.lastname: Fuller
authors.forename: J
authors.initials: J
authors.lastname: Redman
authors.forename: F
authors.initials: F
authors.lastname: Hagemeister
authors.forename: E
authors.initials: E
authors.lastname: Durr
authors.forename: P
authors.initials: P
authors.lastname: Allen
authors.forename: L
authors.initials: L
authors.lastname: Holmes
authors.forename: W
authors.initials: W
authors.lastname: Velasquez
authors.forename: F
authors.initials: F
authors.lastname: Swan
authors.forename: F
authors.initials: F
authors.lastname: Cabanillas
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008207:Lymphatic Metastasis; D008228:Lymphoma, Non-Hodgkin / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009503:Neutropenia / Q000139:chemically induced; D011239:Prednisolone / Q000008:administration & dosage; D011241:Prednisone / Q000008:administration & dosage; D011446:Prospective Studies; D015996:Survival Rate; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D001761:Bleomycin; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone; D011241:Prednisone